ArticleScientific reports2024
Designing a multi-epitope influenza vaccine: an immunoinformatics approach.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Host immune network-guided reverse vaccinology approach for prioritizing candidate antigens in Schistosoma japonicum-associated liver fibrosis.PLoS neglected tropical diseases · 2026Article
- A protocol for computational design of mRNA vaccines with high functionality and specificity.Biology direct · 2026Article
- T-cell-mediated immunity to influenza A (H2N3): implications for caccine efficacy and cross-subtype protection.Archives of microbiology · 2026Review
- An integrated computational antigen discovery pipeline with hierarchical filtering for emerging viral variants.NAR molecular medicine · 2026Article
- Bioinformatics-guided vaccine targeting the hemagglutinin protein of avian influenza virus.Molecular genetics and genomics : MGG · 2026Article
- M13 phage-based antigen presentation and immune response activation in vaccine development for animal infectious diseases.Frontiers in immunology · 2026Review
- Immunoinformatics-driven design of a multi-epitope vaccine againstFrontiers in immunology · 2026Article
- Review
- Field outbreak investigation and immunoinformatic analysis suggest potential immune evasion by Newcastle disease virus Sub-Genotype XIV.2 in Nigeria.Scientific reports · 2025Article
- Consensus-Guided Construction of H5N1-Specific and Universal Influenza a Multiepitope Vaccines.Biology · 2025Article
- A novel mRNA-based multi-epitope vaccine for rabies virus computationally designed via reverse vaccinology and immunoinformatics.Scientific reports · 2025Article
- Immunoinformatics study of CD40 ligand-targeting vaccine constructs: a novel immunotherapeutic approach.Osong public health and research perspectives · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza continues to be one of the top public health problems since it creates annual epidemics and can start a worldwide pandemic. The virus's rapid evolution allows the virus to evade the host defense, and then seasonal vaccines need to be reformulated nearly annually. However, it takes almost half a year for the influenza vaccine to become accessible. This delay is especially concerning in the event of a pandemic breakout. By producing the vaccine through reverse vaccinology and phage display vaccines, this time can be reduced. In this study, epitopes of B lymphocytes, cytotoxic T lymphocytes, and helper T lymphocytes of HA, NA, NP, and M2 proteins from two strains of Influenza A were anticipated. We found two proper epitopes (ASFIYNGRL and LHLILWITDRLFFKC) in Influenza virus proteins for CTL and HTL cells, respectively. Optimal epitopes and linkers in silico were cloned into the N-terminal end of M13 protein III (pIII) to create a multi-epitope-pIII construct, i.e., phage display vaccine. Also, prediction of tertiary structure, molecular docking, molecular dynamics simulation, and immune simulation were performed and showed that the designed multi-epitope vaccine can bind to the receptors and stimulate the immune system response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.